Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML

NCT07493408 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Ph+ Acute Lymphoblastic Leukemia (Ph+ALL)
Blastic Transformation of Chronic Myeloid Leukemia
Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (Ph+ B-ALL)
Haematopoietic Stem Cell Transplant, Allogeneic

Interventions

DRUG: Asciminib add-on
DRUG: Imatinib
DRUG: Dasatinib
DRUG: Nilotinib

Sponsor

The University of Hong Kong

Collaborators

[object Object]
[object Object]